Nutritional Intervention
Nutritional Supplements for Knee Surgery Recovery
Recruiting0 awards
Kingston, Ontario
"This trial aims to investigate whether a combination of essential amino acids and omega-3 fatty acids can help prevent muscle loss and weakness after knee surgery. The study will involve participants taking these supplements before and after
Platinum-based Chemotherapy
Veliparib + Chemoradiation for Advanced Non-Small Cell Lung Cancer
Recruiting0 awardsPhase 1 & 2
Anchorage, Alaska
This trial is studying the side effects and best dose of veliparib when given with radiation therapy, carboplatin, and paclitaxel to see how well it works in treating patients with stage III non-small cell lung cancer.
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Popular Filters
Trials for Breast Cancer Patients
Anti-metabolites
Chemotherapy +/− Bevacizumab for Breast Cancer
Recruiting1 awardPhase 3
Anniston, Alabama
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Trials for LABC Patients
Anti-metabolites
Chemotherapy +/− Bevacizumab for Breast Cancer
Recruiting1 awardPhase 3
Anniston, Alabama
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Trials for HER2 Positive Patients
Anti-metabolites
Chemotherapy +/− Bevacizumab for Breast Cancer
Recruiting1 awardPhase 3
Anniston, Alabama
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Monoclonal Antibodies
T-DM1 for Breast Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trialis testing a drug to see if it works to treat a specific cancer. It has been used in other studies but not yet approved by the FDA. It's being compared to existing treatments to see if it has less side effects and better long-term benefits.
Anti-microtubule agent
Paclitaxel + Trastuzumab + Pertuzumab for Inflammatory Breast Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing the safety and effectiveness of an investigational drug to see if it works in treating a specific cancer. The drug, pertuzumab, is being studied in combination with paclitaxel and trastuzumab as a preoperative treatment for inflammatory breast cancer.
Trials for ER Positive Patients
Anti-metabolites
Chemotherapy +/− Bevacizumab for Breast Cancer
Recruiting1 awardPhase 3
Anniston, Alabama
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Anti-microtubule agent
Atezolizumab + Chemotherapy for HER2-Positive Breast Cancer
Recruiting1 awardPhase 2
Philadelphia, Pennsylvania
This trial is testing a new combination of drugs to treat HER2-overexpressing breast cancer. The new combination includes atezolizumab, which may help the immune system better recognize and kill cancer cells. The trial will test the safety and efficacy of this new combination in 50 patients.
Phase 3 Trials
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
Anti-metabolites
Chemotherapy +/− Bevacizumab for Breast Cancer
Recruiting1 awardPhase 3
Anniston, Alabama
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Trials With No Placebo
Alkylating agents
Chemotherapy +/− Bevacizumab for Ovarian Cancer
Recruiting2 awardsPhase 3
Anchorage, Alaska
This trial is studying carboplatin, paclitaxel, and gemcitabine hydrochloride given together with or without bevacizumab after surgery to treat patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.